StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report released on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The firm has a market cap of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.
About Genocea Biosciences
Featured Stories
- Five stocks we like better than Genocea Biosciences
- Energy and Oil Stocks Explained
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to Use the MarketBeat Dividend Calculator
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.